Jessica W. Borgers

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II Trial.

CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II Trial.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 29, 2026

CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II Trial.

CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II Trial.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

Decitabine reverses innate immune gene suppression in rare melanomas.

Decitabine reverses innate immune gene suppression in rare melanomas.

Journal: Molecular cancer therapeutics

Published: November 04, 2025

Decitabine reverses innate immune gene suppression in rare melanomas.

Decitabine reverses innate immune gene suppression in rare melanomas.

Journal: bioRxiv : the preprint server for biology

Published: September 05, 2025

Publisher Correction: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.

Publisher Correction: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.

Journal: Nature medicine

Published: August 05, 2025

NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy.

NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy.

Journal: Nature communications

Published: June 05, 2025

Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study.

Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study.

Journal: EClinicalMedicine

Published: May 14, 2025

Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update.

Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update.

Journal: Therapeutic advances in medical oncology

Published: March 03, 2025

Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma.

Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma.

Journal: Journal for immunotherapy of cancer

Published: June 09, 2024

Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.

Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.

Journal: Nature medicine

Published: May 31, 2024

Intradermal Naked DNA Vaccination by DNA Tattooing for Mounting Tumor-Specific Immunity in Stage IV Melanoma Patients: A Phase I Clinical Trial.

Intradermal Naked DNA Vaccination by DNA Tattooing for Mounting Tumor-Specific Immunity in Stage IV Melanoma Patients: A Phase I Clinical Trial.

Journal: Oncology research and treatment

Published: December 14, 2023

Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab.

Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab.

Journal: The New England journal of medicine

Published: November 08, 2023

Showing 1-12 of 21

Last Updated: 09/26/2026